Danaher Corporation (DHR) – Bottom line growth with Aldevron acquisition

Danaher announced its plan to acquire Aldevron , which manufactures plasmid DNA, mRNA, and proteins for biotechnology and pharmaceutical customers for $9.6bn.

Highlights 

Valuation

– Enterprise Value
– CrispIdea Forecast
– Economic Value Added Analysis
– DCF Analysis
– P/E Analysis
– Peer Valuation
– CrispIdea Forecast Relative to Consensus
– Consensus History and Surprise
– Consensus Momentum

Actual & Historical Performance

– Income Statement
– Balance Sheet
– Cash Flow
– 10 Year Historical Performance
– Ratio Analysis
– Du Pont Analysis
– ROIC & ROCE Analysis
– Segment Performance
– M&A Deals

Peer Performance

– Summary
– Profitability
– Growth
– Price Performance

Ownership 

Stock Price Performance 

CrispIdea Coverage 

No of Pages : 35